ACROSS DARA REMOVE INTERNATIONAL PATENT APPROVED
Company News
ACROSS DARA REMOVE INTERNATIONAL PATENT APPROVED
Daratumumab (DARA) is an anti-CD38 monoclonal antibody used as a therapeutic agent in relapsed and refractory multiple myeloma cases. DARA causes panagglutination in the Indirect Antiglobulin Test and Cross-Match, affecting blood transfusion compatibility testing. Across Dara Remove has the capability to eliminate the effect of the anti-CD38 antibody in a single simple step. By inhibiting the agglutination effect of Daratumumab, it prevents false-positive reactions in Cross-Match and Indirect Antiglobulin Tests.
We thank Aziz EROĞLU and the R&D Center team for their contributions during the patent application and approval process.
